CS-2164 is under clinical development by Shenzhen Chipscreen Biosciences and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CS-2164’s likelihood of approval (LoA) and phase transition for Non-Hodgkin Lymphoma took place on 14 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CS-2164 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CS-2164 overview

CS-2164 (Chiauranib) is under development for the treatment of small-cell lung cancer, fallopian tube cancer, relapsed and refractory non-Hodgkin lymphoma, epithelial ovarian cancer, liver cancer, ovarian cancer, colorectal cancer, kidney cancer, gastric cancer, lung cancer including non-small cell lung cancer, gastrointestinal stromal tumor, small-cell lung cancer, liver cancer, non-small cell lung carcinoma, colorectal cancer, neuroendocrine tumors, hepatocellular carcinoma, ovarian cancer, breast cancer, peritoneal carcinoma, soft tissue sarcoma, triple-negative breast cancer (TNBC), HER2- Breast Cancer and other solid tumors and soft tissue sarcomas including liposarcoma, leiomyosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma, fibrosarcoma Sarcoma, clear cell sarcoma, angiosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor, undifferentiated sarcoma, Ewing's sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberanoma, myofibroblastic sarcoma, malignant solitary fibroma, radiotherapy Posterior sarcoma, acinar soft tissue sarcoma, well-differentiated/dedifferentiated liposarcoma. It is administered orally as a capsule. The drug candidate is a small molecule. It acts by targeting aurora B, PDGFR, c-kit, vascular and endothelial growth factor receptor. The drug candidate is developed using chemical genomics-based discovery platform. It was also under development for the treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma, renal cell carcinoma.

Shenzhen Chipscreen Biosciences overview

Shenzhen Chipscreen Biosciences (Chipscreen) operates as a biotechnology company that discovers and develops proprietary small molecule therapeutics for pharmaceutical and drug development. The company’s pipeline products include Chidamide, Chiglitazar, Chiauranib, CS3158, CS510, CS410, CS2164 and MeiGanLe. Its Chidamide chidamide is a novel subtype selective HDAC inhibitor functioning as an epigenetic modulator for the treatment of various haematological and solid cancers. Chipscreen offers protocol design, clinical research and monitoring, and data analysis and management services. The company provides clinical and preclinical stage programs in various therapeutic areas. Chipscreen is headquartered in Shenzhen, China.

Quick View CS-2164 LOA Data

Report Segments
  • Innovator
Drug Name
  • CS-2164
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.